Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"monophosphoryl lipid A"”.
-
Mechanisms of Immuno-Modulation With The TLR4 Agonist Monophosphoryl Lipid A in the Treatment of Sepsis
Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4 agonist that has been approved for use as a vaccine adjuvant in humans. In these studies, we evaluated the effect of MPLA treatment on the innate immune response to systemic infection in mice with emphasis on bacterial clearance, leukocyte …
-
Lipid-coated micro- and nanoparticles as a biomimetic vaccine delivery platform
… a system for vaccine delivery that uses a "lipid surfactants" approach to combine a degradable polymer core with a two-dimensionally fluid lipid bilayer shell. Using optical and electron microscopy, we characterized the distribution, lamellarity, nanostructure, and mobility of the lipid …
-
Enhancement of HIV vaccine efficacy via lipid nanoparticle-based adjuvants
… in the Irvine lab, we determined the potency of lipid-coated microparticles was due in part to the in situ generation of antigen-displaying liposomes. Synthetic liposomes were nearly as potent as lipid-coated microparticles, but with a 10-fold greater antigen conjugation efficiency. We …
-
Factors that Affect the Immunogenicity of Lipid-PLGA Nanoparticle-Based Nanovaccines against Nicotine Addiction
… to their intrinsic shortfalls. In this study, a lipid-poly(lactic-co-glycolic acid) (PLGA) nanoparticle-based next-generation nicotine vaccine has been developed to overcome the drawbacks of conjugate nicotine vaccines. Also, the influence of multiple factors, including nanoparticle size, hapten …
-
Evaluation of the novel P particle vaccine candidate against human norovirus using the gnotobiotic pig challenge model
… at post-inoculation day (PID) 0, 10, and 21. Monophosphoryl lipid A and chitosan were used as mucosal adjuvants. At PID 28, a subset of pigs were orally challenged with 10 median infectious doses (ID50) NoV. NoVPO, LoPP, HiPP, and VLPs provided partial protection from diarrhea (83%, 47%, 60%, …
-
Immunization with synthetic nanoparticles to generate mucosal CD8 T Cell responses
… 2 different Toll-like receptor agonists (TLRa), monophosphoryl lipid A (MPLA) and Polyinosinic:polycytidylic acid (poly (I:C) or pIC) added to ICMVs as adjuvants. Pulmonary administration of ICMV with both adjuvants was found to give the most potent CD8 T cell response in both systemic and …
-
Immunoprotective effects of lipopolysaccharide detoxification by a novel microbial-derived alkaline phosphatase
… the release of an inorganic phosphate from the lipid A moiety of LPS, resulting in the considerably less immunostimulatory product, monophosphoryl lipid A (MPLA). Based on IAP’s ability to reduce the inflammatory effects of LPS in the GIT and the difficulty in creating a viable commercial …
-
Layer-by-Layer Nanoparticles for Cytokine Delivery
… OC. Aspects on the manufacturing of other lipid-based nanocarriers such as discoidal assemblies and immune stimulating complexes (ISCOMs) are also explored. We show that employing a bottom-up approach to produce lipid-based NPs from mixed micelles allows for greater control over NP …
-
New Carbohydrate-Based Anti-Cancer And Anti-Bacterial Vaccines
… has also developed new vaccine carriers, such as monophosphoryl lipid A (MPLA), to construct full-synthetic carbohydrate-based vaccines that have well-defined structures and improved immunological properties. The main aims of this dissertation are to study</p> <p>and evaluate these semi- and …